Oncology Research and Treatment
Journal Abbreviation: Oncol Res Treat
ISSN: 2296-5270
eISSN: 2296-5262
Publisher: Karger Publishers
Publications (241)
Response to 6 cycles of chemotherapy with FOLFIRINOX is predictive of overall survival in patients with locally advanced unresectable pancreatic cancer (2016)
Haderlein M, Lubgan D, Lettmaier S, Semrau S, Wolf W, Golcher H, Hohenberger W, Fietkau R
Conference contribution
LOGIST - A local observational GIST registry: A non-interventional registry to observe patients with gastrointestinal stromal tumors (GIST) after R0/R1 resection - with or without adjuvant therapy with imatinib (CSTI571BDE77) - an interim analysis with 5 (2016)
Reichardt P, Quietzsch D, Stuebs P, Cameron S, Gellert K, Wilhelm M, Killing B, et al.
Conference contribution
Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer (2016)
Janni W, Schramm A, Friedl TWP, Schochter E, Huober J, Rack B, Alunni-Fabbroni M, et al.
Conference contribution
Effective long-term local results and prognostic factors after fractionated stereotactic radiotherapy of 257 intracranial meningeoma (2016)
Lubgan D, Rutzner S, Semrau S, Lambrecht U, Roessler K, Buchfelder M, Fietkau R
Conference contribution
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016)
Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al.
Conference contribution
The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016)
Schramm A, Friedl T, Rack B, Trapp E, Fasching P, Taran FA, Hartkopf A, et al.
Conference contribution
TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs) (2016)
Tzschaschel M, Trapp E, Rack B, Messina C, Mueller V, Fehm T, Janni W, et al.
Conference contribution
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016)
Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al.
Conference contribution
Tumor infiltrating cells - cell-to-cell distances enable differentiation between functionally active and suppressed inflammatory cells (2016)
Distel L, Nagl S, Fietkau R, Haas M
Conference contribution
The Treatment Reality of Octogenarians with Bladder Cancer in a Maximum Care Hospital (2016)
Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Lieb V, Krause S, et al.
Conference contribution